NCT03562819View on ClinicalTrials.gov

Study to Evaluate Concordance of Detecting EGFR (Epidermal Growth Factor Receptor) Mutation by Circulating Tumour Free DNA Versus Tissues Biopsy in NSCLC (Non-small Cell Lung Cancer).

CompletedOBSERVATIONAL
Enrollment

268

Participants

Timeline

Start Date

August 16, 2018

Primary Completion Date

June 7, 2019

Study Completion Date

June 7, 2019

Conditions
NSCLC (Non-small Cell Lung Cancer)
Trial Locations (14)

110029

Research Site, New Delhi

110063

Research Site, New Delhi

110085

Research Site, New Delhi

160055

Reserch Site, Punjab

400012

Research Site, Mumbai

400016

Research Site, Maharashtra

400071

Research Site, Mumbai

500034

Research Site, Hyderabad

560027

Research Site, Bengaluru

673601

Research Site, Kerala

700054

Research Site, Kolkata

700063

Research Site, Kolkata

700160

Research Site, Kolkata

751007

Research Site, Bhubaneswar

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT03562819 - Study to Evaluate Concordance of Detecting EGFR (Epidermal Growth Factor Receptor) Mutation by Circulating Tumour Free DNA Versus Tissues Biopsy in NSCLC (Non-small Cell Lung Cancer). | Biotech Hunter | Biotech Hunter